Status: Closed
ClinicalTrials.gov Identifier: NCT02418754
Regeneron CAPELLA R2176-3AMD-1417: A Phase 2, Double-masked, Randomized, Controlled, Multiple-dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-related Macular Degeneration
Condition: Neovascular AMD
Study Type: Interventional
Duration: 52 weeks
Eligibility:
For additional information, please click here
Back to Clinical Research